May 16 2024UCD Research & Innovation In the international CONVINCE trial, presented today at the European Stroke Organisation Conference 2024, anti-inflammatory treatment with long-term colchicine did not reduce rates of recurrent stroke and cardiovascular events in patients with non-cardioembolic stroke in the primary intention-to-treat analysis.
CONVINCE was an international, randomised, open-label trial designed to test whether long-term colchicine in addition to standard of care reduces recurrent stroke or cardiovascular events in patients with non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack . The primary endpoint was a composite of first recurrent ischaemic stroke, myocardial infarction, cardiac arrest or hospitalisation for unstable angina.